Neuraegis

NeurAegis Inc., based in Pomona, CA, is a neuropharmaceutical company in the late preclinical stage focused on developing innovative treatments for neurological disorders, primarily targeting traumatic brain injury (TBI) and concussion. With no FDA-approved treatments available for these conditions, the company is pioneering novel protease inhibitors that address the critical need for effective therapies.

With a significant public health concern surrounding TBI, which reports over 3.8 million sports- and recreation-related concussions annually in the U.S., NeurAegis is committed to advancing solutions where current options are lacking. The company has secured substantial funding, including a $3.8 million grant from the Department of Defense, to expedite their research in this vital area of healthcare.

Generated from the website